New York Attorney General Letitia James has successfully reached a five-year agreement with Denmark-based Novo Nordisk to cap the price of insulin at $35 per month for uninsured individuals residing in New York. Insulin, a life-saving medication for people with diabetes, has seen significant price hikes by leading insulin manufacturers such as Eli Lilly, Novo Nordisk, and … [Read more...] about New York Attorney General Secures Deal to Cap Insulin Prices
Forex News
Coco Gauff’s Historic Win at the U.S. Open
At just 19 years old, Coco Gauff proved herself as a force to be reckoned with in the world of tennis by claiming her first Grand Slam title. In a thrilling match against Aryna Sabalenka, Gauff displayed her tenacity and skill, ultimately winning 2-6, 6-3, 6-2 in the U.S. Open final. A Triumph for Young American Tennis Hailing from Florida, Gauff is now the first American … [Read more...] about Coco Gauff’s Historic Win at the U.S. Open
Makers of Discretionary Consumer Goods Poised for Success
Retail sales experienced a notable increase of 3.2% in July compared to the previous year, surpassing June's growth rate of 1.2%. This surge indicates a positive trend in consumer spending, defying the Federal Reserve's efforts to curb demand for goods and services. Economists believe this trend will continue as the Federal Reserve nears the end of its endeavor to combat … [Read more...] about Makers of Discretionary Consumer Goods Poised for Success
Olam Group Denies Allegations of Multi-Billion Dollar Fraud
Olam Group has strongly refuted recent news reports claiming that its Nigerian units and subsidiaries were involved in a significant fraud valued in the billions of dollars. The company dismissed these allegations as "baseless and inflammatory statements" in a filing to the Singapore exchange. The reports, sourced from the Daily Nigerian newspaper and Prime Business Africa, … [Read more...] about Olam Group Denies Allegations of Multi-Billion Dollar Fraud
Neumora Therapeutics Plans IPO
Neumora Therapeutics, a clinical-stage biopharmaceutical company specializing in brain diseases, has announced its plan to launch an initial public offering (IPO) to raise capital. Backed by Amgen, the company intends to sell 14.7 million shares at a price range of $16 to $18 per share. At the midpoint of $17 per share, Neumora expects to generate approximately $227.5 million … [Read more...] about Neumora Therapeutics Plans IPO
